SNAP-CAR recognized in research detailing
advances in modulating chimeric antigen receptor (CAR) T cell
activity for improved safety, efficacy, and flexibility
WEXFORD,
Pa., March 21, 2023 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the
Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, announced that its SNAP-CAR
technology was highlighted in a peer-reviewed article published in
the Journal of Translational Medicine. SNAP-CAR is a
multi-antigen chimeric antigen receptor T cell (CAR T) technology
that can be adapted to different cancer indications, including
hematologic and solid tumors.
The article titled, "Tuning CARs: recent advances in modulating
chimeric antigen receptor (CAR) T cell activity for improved
safety, efficacy, and flexibility," discusses a variety of efforts
and cross field collaborations striving to balance anti-tumor
activity of next-generation cell therapies that also minimize
harmful side effects associated with CAR-T. The article describes
SNAP-CAR as an "up-and-coming" technology that covalently links
therapeutic monoclonal antibodies (mAbs) to universal CAR
receptors, with demonstrated function in vitro and in
vivo, and represents a "powerful concept for overcoming
suboptimal CAR functions due to the lower affinity of soluble
adaptors to universal CAR receptors."
"We are pleased that SNAP CAR was featured in this peer-reviewed
article, which highlights the latest developments in CAR T
technologies designed to improve cell therapy outcomes and mitigate
associated toxicities to enable improved safety, efficacy, and
flexibility," said Dave Mehalick,
President and CEO of Coeptis Therapeutics. "Research conducted at
the University of Pittsburgh suggests
that SNAP-CAR offers an opportunity to direct the power of CAR T to
an array of cancers that have, until now, been inaccessible via
current cell therapy technologies by providing a highly
programmable antigen targeting platform. SNAP-CAR T cells can be
engineered to address numerous cancers, including HER2-expressing
ovarian cancer, which we are targeting as our potential
first-in-human clinical development program."
About SNAP-CAR
SNAP-CAR, which Coeptis Therapeutics licensed from the
University of Pittsburgh, is designed
to be a "universal" CAR T cell therapy platform that can be adapted
to different cancer indications. Instead of directly binding to a
target on the tumor cell, CAR T cells are co-administered with one
or more antibody adaptors that bind to the tumor cells and are
fitted with a chemical group that irreversibly connects them to the
SNAP-CAR on the therapeutic cells via a covalent bond. Pre-clinical
studies in mice have demonstrated that by targeting tumors via
antibody adaptor molecules, the SNAP-CAR therapy provides a highly
programmable therapeutic platform.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer
that have the potential to disrupt conventional treatment paradigms
and improve patient outcomes. Coeptis' product portfolio and rights
are highlighted by a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and a cell therapy technology
(CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic)
targeting CD38-related cancers, which Coeptis is
developing with VyGen-Bio and leading medical researchers at
the Karolinska Institutet. Coeptis' business model is designed
around maximizing the value of its current product portfolio and
rights through in-license agreements, out-license agreements and
co-development relationships, as well as entering into strategic
partnerships to expand its product rights and offerings,
specifically those targeting cancer. The Company is headquartered
in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Global Market following the business combination; (2) the risk that
the business combination disrupts current plans and operations of
Company as a result of the consummation of the business
combination; (3) the inability to recognize the anticipated
benefits of the business combination, which may be affected by,
among other things, competition, the ability of the Company to grow
and manage growth economically and hire and retain key employees;
(4) the risks that the Company's products in development fail
clinical trials or are not approved by the U.S. Food and Drug
Administration or other applicable regulatory authorities; (5)
costs related to the business combination; (6) changes in
applicable laws or regulations; (7) the possibility that the
Company may be adversely affected by other economic, business,
and/or competitive factors; and (8) the impact of the global
COVID-19 pandemic on any of the foregoing risks and other risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission (the "SEC"). The foregoing list
of factors is not exclusive. All forward-looking statements are
subject to significant uncertainties and risks including, but not
limited, to those risks contained or to be contained in reports and
other filings filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance
upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings made or
to be made with the SEC, which are available for review
at www.sec.gov. We undertake no obligation to publicly revise these
forward-looking statements to reflect events or circumstances that
arise after the date hereof unless required by applicable laws,
regulations, or rules.
CONTACTS
Coeptis Therapeutics,
Inc.
Andy Galy, Sr. VP of
Communications
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Jon Nugent
jnugent@tiberend.com
Media
David
Schemelia
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-snap-car-technology-platform-highlighted-in-peer-reviewed-article-in-translational-medicine-301776628.html
SOURCE Coeptis Therapeutics